Literature DB >> 18607832

MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium.

Ruthy Shaco-Levy1, Shalom Sharabi, Benjamin Piura, Netta Sion-Vardy.   

Abstract

OBJECTIVE: To investigate the expression of MMP-2, TIMP-1, E-cadherin and beta-catenin in endometrial serous carcinoma (ESC), low-grade endometrial endometrioid carcinoma (EEC), and proliferative endometrium.
METHODS: We performed an immunohistochemical study on 14 cases of ESC, 15 cases of low-grade EEC, and 10 cases of proliferative endometrium.
RESULTS: Compared with low-grade EEC, ESC showed significantly increased MMP-2 and TIMP-1 expression, as well as decreased membranous beta-catenin staining. E-cadherin expression was significantly lower in ESC and EEC as compared with proliferative endometrium.
CONCLUSIONS: We suggest that MMP-2 and TIMP-1 expression and loss of beta-catenin have a role in the pathogenesis and progression of ESC. Decreased E-cadherin may have an important role in the development of both ESC and EEC. Furthermore, the dissimilarities in MMP-2, TIMP-1, E-cadherin and beta-catenin expressions in ESC compared with EEC may be responsible, along with other factors, for their different biological behavior.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18607832     DOI: 10.1080/00016340802253775

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  9 in total

1.  Increased incidence of endometrioid tumors caused by aberrations in E-cadherin promoter of mismatch repair-deficient mice.

Authors:  Irina V Kovtun; Kimberly J Harris; Aminah Jatoi; Dragan Jevremovic
Journal:  Carcinogenesis       Date:  2011-05-05       Impact factor: 4.944

2.  Loss of CDH1 and Pten accelerates cellular invasiveness and angiogenesis in the mouse uterus.

Authors:  Mallory E Lindberg; Genna R Stodden; Mandy L King; James A MacLean; Jordan L Mann; Francesco J DeMayo; John P Lydon; Kanako Hayashi
Journal:  Biol Reprod       Date:  2013-07-11       Impact factor: 4.285

3.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

4.  Controversies in the management of endometrial carcinoma.

Authors:  Ying Zhang; Jian Wang
Journal:  Obstet Gynecol Int       Date:  2010-06-22

5.  Expression of matrix metalloproteinase-2 and survivin in endometrioid and nonendometrioid endometrial cancers and clinicopathologic significance.

Authors:  Evren Yilmaz; Meral Koyuncuoglu; Ilknur Bilkay Görken; Emre Okyay; Bahadir Saatli; Emine Cagnur Ulukus; Ugur Saygili
Journal:  J Gynecol Oncol       Date:  2011-06-30       Impact factor: 4.401

6.  Tissue microarray is suitable for scientific biomarkers studies in endometrial cancer.

Authors:  Nicole C M Visser; Anneke A M van der Wurff; Johanna M A Pijnenborg; Leon F A G Massuger; Johan Bulten; Iris D Nagtegaal
Journal:  Virchows Arch       Date:  2018-02-09       Impact factor: 4.064

7.  Interplay between Misplaced Müllerian-Derived Stem Cells and Peritoneal Immune Dysregulation in the Pathogenesis of Endometriosis.

Authors:  Antonio Simone Laganà; Emanuele Sturlese; Giovanni Retto; Vincenza Sofo; Onofrio Triolo
Journal:  Obstet Gynecol Int       Date:  2013-06-13

8.  Loss of Cdh1 and Trp53 in the uterus induces chronic inflammation with modification of tumor microenvironment.

Authors:  G R Stodden; M E Lindberg; M L King; M Paquet; J A MacLean; J L Mann; F J DeMayo; J P Lydon; K Hayashi
Journal:  Oncogene       Date:  2014-07-07       Impact factor: 9.867

9.  Combination of strong MMP-2 and weak TIMP-2 immunostainings is a significant prognostic factor in endometrial carcinoma.

Authors:  Maria Honkavuori-Toivola; Markku Santala; Ylermi Soini; Taina Turpeenniemi-Hujanen; Anne Talvensaari-Mattila
Journal:  Dis Markers       Date:  2013       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.